HIV / AIDS

The pivotal phase 3 AMBER study regarding the safety and efficacy of the investigational darunavir-based single tablet HIV regimen has achieved its primary endpoint.

Although there have been important improvements to existing vaccines, the list of vaccine-preventable diseases has barely changed at all in over two decades.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A pair of papers published in the Journal of Infectious Diseases highlight the effort to fight and monitor drug-resistant HIV, which poses a threat to achieving the global targets designed to end the AIDS epidemic.

Based on WHO guidelines for tuberculosis screening, many individuals who don’t have the disease are sent for expensive confirmatory testing. A simple point-of-care blood test could change all of that.

Brinda Emu, MD, offers insight into the HIV monoclonal antibody ibalizumab.

Dr. Shibani Mukerji discusses how HIV affects the brain as part of a symposium at ID Week 2017.

A new literature review of 60 papers and studies finds that voluntary medical male circumcision programs in Africa also have benefits for women’s health.

NIAID director Dr. Anthony S. Fauci stresses in a recent commentary that, from a practical standpoint, the development of a moderately effective HIV vaccine is “essential” to ending the pandemic.

A total of 5 HIV cure research initiatives will receive $7.5 million as recipients of Gilead’s HIV cure grants program.

Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.

Jessica Justman, MD, shares how the PHIA project is collecting HIV biomarkers in children.

Having herpes simplex 2 puts individuals at greater risk of contracting HIV, and vice versa, largely due to increased genital ulceration and viral shedding.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Investigators presented advances in basic and clinical research on infectious diseases and HIV in the past year at ID Week.

The results of a 5-year study show that coffee drinking can cut down the risk of all-cause mortality in patients with HIV and hepatitis C virus (HCV) infections.

Investigators describe the current state of identification and management of fungal diseases, and discuss potential approaches for improving their recognition and treatment

A Phase 2 study showed that maraviroc-containing antiretroviral regimens were generally safe and well-tolerated in a female population.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Alex Rinehart, PhD, explains how the development of a long-acting injectable offers a new preventive option for HIV.

Death rates among HIV-positive patients diagnosed with cryptococcal meningitis were slightly lower when antiretroviral therapy was delayed a few weeks after diagnosis.

Made of a flexible silicone material, the ring contains dapivirine, a non-nucleoside reverse transcriptase inhibitor that blocks HIV’s ability to replicate inside of a healthy cell.

Case Western Reserve University School of Medicine researchers identify accentuated risks for age-associated comorbidities in those living with HIV.

Hanneke Schuitemaker, PhD, explains the challenges faced when creating a vaccine for HIV.

Magda Opsomer, MD, shares the results of the Phase 3 EMERALD trial for darunavir.